Genzyme ($GENZ) meets FDA consent decree deadline

Genzyme ($GENZ), subject to a hostile bid by Sanofi-Aventis ($SNY), said it has satisfied a key component of a consent decree imposed by U.S. regulators after a crisis at its Boston manufacturing facility led to shortages of two key drugs. Report

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.